abstract_id,session_title,abstract_title,ground_truth,default_model_primary_drugs,default_model_secondary_drugs,default_model_comparator_drugs,default_model_reasoning,default_model_success,default_model_llm_calls
6022,,"A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma",,"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone"", ""Orelabrutinib"", ""Chidamide"", ""Venetoclax"", ""Lenalidomide"", ""Penpulimab""]",[],"[""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Vincristine"", ""Prednisone"", ""Orelabrutinib"", ""Chidamide"", ""Venetoclax"", ""Lenalidomide"", ""Penpulimab"", ""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]","[""1. Normalized title and identified all drug and regimen mentions."", ""2. Detected 'Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab' as the main experimental arm (Pola-RCHP-X)."", ""3. Expanded all regimen abbreviations: RCHOP-X (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab), Pola-RCHP (Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone)."", ""4. 'Versus' indicates comparator arms: RCHOP-X and Pola-RCHP."", ""5. Excluded regimen abbreviations since expanded drug names are present."", ""6. Classified all drugs in the experimental arm as Primary."", ""7. Classified all drugs in the comparator arms as Comparator, ensuring no duplicates and including all drugs from both RCHOP-X and Pola-RCHP."", ""8. No secondary drugs identified per inclusion/exclusion rules."", ""9. Applied formatting rules and validated output JSON.""]",True,1
148,,Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial,,"[""BrECADD"", ""eBEACOPP""]",[],[],"[""1. Normalized title and identified candidate drug regimens: BrECADD and eBEACOPP."", ""2. Both BrECADD and eBEACOPP are regimen abbreviations; no expanded drug names are present in the title."", ""3. Inclusion rules allow capturing regimen abbreviations when expanded forms are not present."", ""4. No comparator or secondary identifiers (e.g., 'vs', 'with or without') are present."", ""5. Excluded 'chemotherapy' as a broad therapy term per exclusion rules."", ""6. Classified BrECADD and eBEACOPP as Primary Drugs since they are the main regimens administered."", ""7. Formatted output per guidelines.""]",True,1
671,,Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma:a Phase 2 Multicenter Study,,[],[],[],"[""1. Normalized title and identified candidate drug-like phrases: 'Novel Targeted Agents', 'R-MINE (RMINE+X)'"", ""2. 'Novel Targeted Agents' is a general term, not a specific drug name, so excluded per exclusion rules."", ""3. 'R-MINE' is an abbreviated regimen; checked for expanded drug names in the title, but none are present."", ""4. Per inclusion rules, only capture abbreviated regimens if expanded names are not present; however, 'R-MINE' is not a standard 2\u20133 letter regimen and its components are not specified."", ""5. 'RMINE+X' refers to R-MINE plus an unspecified agent; 'X' is not a drug name."", ""6. No specific drug names or regimens suitable for inclusion are present in the title."", ""7. No comparator or secondary drugs identified."", ""8. Output empty arrays for all categories.""]",True,1
4792,,"A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics",,"[""Glofitamab"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Vincristine"", ""Prednisolone"", ""Polatuzumab Vedotin""]",[],[],"[""1. Normalized title and identified candidate drug-containing regimens: Glofitamab-R-CHOP and Glofitamab-Polatuzumab Vedotin-R-CHP."", ""2. Expanded R-CHOP to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone per inclusion rules; R-CHP to Rituximab, Cyclophosphamide, Doxorubicin, Prednisolone."", ""3. Polatuzumab Vedotin is explicitly named and included."", ""4. 'or' indicates both regimens are primary arms; all drugs in both regimens are classified as Primary."", ""5. Excluded broad therapy terms and diagnostic agents (FDG-PET) per exclusion rules."", ""6. No secondary or comparator drugs identified."", ""7. Applied formatting rules and produced final JSON.""]",True,1
2723,,Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel,,"[""Idecabtagene Vicleucel"", ""Ciltacabtagene Autoleucel""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Idecabtagene Vicleucel, Ciltacabtagene Autoleucel."", ""2. Both drugs are CAR-T cell therapies and are the focus of treatment in multiple myeloma patients."", ""3. 'Treated with' indicates these drugs are administered as primary therapies."", ""4. No secondary or comparator identifiers present in the title."", ""5. Applied formatting rules and confirmed output structure.""]",True,1
2983,,The Effects of Tranexamic Acid and Recombinant Activated Factor VII on Traumatic Bleeding and Mortality in Mice,,"[""Tranexamic Acid"", ""Recombinant Activated Factor VII""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Tranexamic Acid, Recombinant Activated Factor VII."", ""2. Detected 'and' as a co-administration identifier, indicating both drugs are being studied as primary interventions."", ""3. No phrases indicating secondary or comparator drugs (e.g., 'with or without', 'vs', 'compared to') were present."", ""4. Excluded any non-drug terms; both identified drugs are included per inclusion rules."", ""5. Applied formatting rules: maintained title casing, separated drugs with ';;' if needed."", ""6. Produced final JSON with both drugs as Primary, others as empty arrays.""]",True,1
3344,,Real World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma,,"[""Axicabtagene Ciloleucel"", ""Lisocabtagene Maraleucel""]",[],[],"[""1. Normalized title and identified drug-like phrases: Axicabtagene Ciloleucel, Lisocabtagene Maraleucel."", ""2. Detected 'comparison of' indicating both drugs are being evaluated as primary treatments."", ""3. No explicit comparator arm (e.g., 'vs standard therapy') is mentioned; both drugs are the focus."", ""4. No secondary drugs or comparator drugs identified per classification rules."", ""5. Applied formatting rules and confirmed output structure.""]",True,1
3677,,Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide,,"[""Belantamab Mafodotin"", ""Pomalidomide"", ""Dexamethasone""]",[],"[""Pomalidomide"", ""Bortezomib"", ""Dexamethasone""]","[""1. Normalized title and identified candidate drug phrases: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib, Lenalidomide."", ""2. Detected 'plus' and 'and' indicating co-administration for both arms; 'vs' indicates comparator arm."", ""3. First arm: 'Belantamab Mafodotin Plus Pomalidomide and Dexamethasone'\u2014all three are Primary."", ""4. Comparator arm: 'Pomalidomide Plus Bortezomib and Dexamethasone'\u2014all three are Comparator."", ""5. Lenalidomide is mentioned only as prior therapy, so excluded per exclusion rules."", ""6. Applied formatting rules: proper casing, separator, and no duplicates."", ""7. Produced final JSON output.""]",True,1
564,,"Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) Results in Higher Remission Rates over Conventional 7+3 Chemotherapy without Increased Toxicity in Newly Diagnosed Acute Myeloid Leukemia",,"[""Venetoclax"", ""Cladribine"", ""Idarubicin"", ""Cytarabine""]",[],[],"[""1. Normalized title and identified candidate drug/regimen phrases: Venetoclax, Cladribine, Idarubicin, Cytarabine (CLIA), 7+3 Chemotherapy."", ""2. Expanded CLIA to individual drugs as per inclusion rules; excluded CLIA abbreviation since full names are present."", ""3. 'Venetoclax Combined with Cladribine, Idarubicin, Cytarabine' indicates all four are co-administered as Primary drugs."", ""4. 'over Conventional 7+3 Chemotherapy' suggests a comparator, but 7+3 is a regimen name without explicit drug names in the title; per inclusion rules, do not capture regimen abbreviations if drug names are not specified."", ""5. Excluded 'chemotherapy' as a broad therapy term per exclusion rules."", ""6. No secondary drugs identified (no 'with or without', '\u00b1', etc. phrases)."", ""7. Formatted output per guidelines.""]",True,1
876,,Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs,,"[""CD5-Targeted CAR-T Cell"", ""CD7-Targeted CAR-T Cell""]",[],[],"[""1. Normalized title and identified candidate therapies: CD5-Targeted CAR-T Cell, CD7-Targeted CAR-T Cell, Allogeneic HSCs."", ""2. 'Tandem CAR-T-Cell Therapy Targeting CD5 and CD7' indicates both CD5-Targeted and CD7-Targeted CAR-T Cells are administered as primary therapies."", ""3. 'Allogeneic HSCs' refers to hematopoietic stem cells, but context is engraftment/facilitation, not direct therapeutic administration for disease treatment."", ""4. Excluded Allogeneic HSCs per cell therapy rules (not administered as treatment in this context)."", ""5. No secondary or comparator drugs identified."", ""6. Applied formatting and naming conventions for CAR-T variants."", ""7. Produced final JSON output.""]",True,1
4835,,"Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL",,"[""CD19-Directed CAR-T Cell"", ""CD22-Directed CAR-T Cell"", ""Allogeneic Hematopoietic Cell""]",[],[],"[""1. Normalized title and identified candidate drug/cell therapy terms: CD19/CD22-CAR T Cells, Allo-HCT."", ""2. Split 'CD19/CD22-CAR T Cells' into 'CD19-Directed CAR-T Cell' and 'CD22-Directed CAR-T Cell' per cell therapy rules."", ""3. Interpreted 'Allo-HCT' as 'Allogeneic Hematopoietic Cell' per stem cell therapy normalization rules."", ""4. 'with' indicates co-administration, so all are classified as Primary."", ""5. No secondary or comparator drugs identified."", ""6. Applied formatting and naming conventions for CAR-T and cell therapies."", ""7. Produced final JSON output.""]",True,1
3429,,"ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs",,"[""Asciminib""]",[],[],"[""1. Normalized title and identified candidate drug terms: Ascembl Study, Asciminib, TKIs."", ""2. 'Ascembl Study' is a study name, not a drug; 'TKIs' is a broad drug class and excluded per exclusion rules."", ""3. 'Asciminib' is the only specific drug mentioned and is the focus of both the clinical trial and real-world evidence comparison."", ""4. No comparator drug is specified; comparison is between study types, not different drugs."", ""5. Classified Asciminib as Primary per inclusion rules."", ""6. Applied formatting rules and validated output JSON.""]",True,1
3489,,Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up,,"[""Ibrutinib""]",[],[],"[""1. Normalized title and identified drug-like phrases: Ibrutinib."", ""2. Detected 'First-Line Ibrutinib' as the main therapeutic agent studied for CLL treatment."", ""3. No secondary or comparator drugs mentioned; no combination or comparison identifiers present."", ""4. Excluded general terms and study references per exclusion rules."", ""5. Classified Ibrutinib as Primary and formatted output per guidelines.""]",True,1
4343,,Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia,,"[""Revumenib""]",[],[],"[""1. Normalized title and identified candidate drug-like terms: Revumenib."", ""2. Detected 'Revumenib' as the only specific drug mentioned; no combination, secondary, or comparator identifiers present."", ""3. 'Revumenib' is administered for treatment in relapsed/refractory KMT2Ar acute leukemia, making it the Primary drug."", ""4. No other drugs or regimens detected; excluded general terms and disease names per exclusion rules."", ""5. Applied formatting rules and produced final JSON.""]",True,1
4356,,Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia,,"[""Enzomenib""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: Menin-MLL Inhibitor Enzomenib (DSP-5336)"", ""2. 'Enzomenib (DSP-5336)' is the specific drug name; Menin-MLL Inhibitor is a mechanism/class and excluded per exclusion rules"", ""3. No secondary or comparator drugs detected; no relevant identifiers present"", ""4. Classified Enzomenib as Primary as it is the main therapeutic agent under study"", ""5. Applied formatting rules and output final JSON""]",True,1
4460,,Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study,,"[""Rituximab""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: Watchful Waiting, Rituximab."", ""2. 'Vs.' indicates a comparison; Rituximab is compared to Watchful Waiting."", ""3. 'Watchful Waiting' is not a drug or regimen, so excluded per exclusion rules."", ""4. Rituximab is the only therapeutic drug administered as first-line treatment, classified as Primary."", ""5. No valid comparator drug (Watchful Waiting is not a drug), so Comparator Drugs array left empty."", ""6. Applied formatting rules and verified output.""]",True,1
4461,,"Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from ""FOLL12"" Phase III Trial of the Fondazione Italiana Linfomi",,"[""Rituximab""]",[],[],"[""1. Normalized title and identified candidate drug-related phrases: Rituximab Maintenance."", ""2. Detected 'Rituximab' as a specific drug used for maintenance therapy in follicular lymphoma."", ""3. No other drug names, regimens, or cell therapies present; 'Minimal Residual Disease Analysis' is a diagnostic/prognostic term and excluded."", ""4. 'Rituximab Maintenance' indicates Rituximab is administered for therapeutic use, classified as Primary."", ""5. No secondary or comparator drugs identified."", ""6. Applied formatting rules and produced final JSON.""]",True,1
4617,,"ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia",,"[""Mitapivat""]",[],[],"[""1. Normalized title and identified candidate drug-like terms: Mitapivat, Placebo."", ""2. 'Mitapivat' is the only named drug; 'Placebo' is excluded per exclusion rules."", ""3. 'Placebo-Controlled' indicates a comparator arm, but placebo is not captured."", ""4. No secondary drug identifiers (e.g., 'with or without', 'and/or') present."", ""5. Classified Mitapivat as Primary drug per guidelines."", ""6. Applied formatting rules and verified output.""]",True,1
4724,,Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial,,"[""Lacutamab""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: Lacutamab."", ""2. Detected 'treated by Lacutamab' indicating Lacutamab is the main therapeutic agent studied."", ""3. No secondary or comparator drugs mentioned; no relevant identifiers for those categories."", ""4. Excluded general terms and ensured only drugs intended for treatment are captured."", ""5. Applied formatting rules and produced final JSON.""]",True,1
4751,,"Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)",,"[""Divesiran""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: Divesiran, Galnac Conjugated siRNA."", ""2. Divesiran is described as a novel agent being evaluated, indicating it is the main therapeutic under study."", ""3. 'Galnac Conjugated siRNA' is a description of Divesiran's molecular type, not a separate drug; per exclusion rules, mechanism/class terms are omitted."", ""4. No secondary or comparator drugs are mentioned."", ""5. Applied formatting rules and outputted only Divesiran as Primary.""]",True,1
4866,,A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3,,"[""Ianalumab""]",[],[],"[""1. Normalized title and identified drug-like terms: Ianalumab."", ""2. Detected 'Ianalumab' as the only specific drug administered for treatment in the study."", ""3. Phrase 'previously treated with at least two lines of therapy' refers to prior treatments and does not specify drugs for extraction."", ""4. No comparator or secondary drugs are mentioned."", ""5. Applied formatting and exclusion rules; output only Ianalumab as Primary.""]",True,1
5173,,"HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30+ T Cell Lymphoma: Clinical Results of a Phase I/II Trial",,"[""HSP-CAR30"", ""Memory-Enriched CART30""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: HSP-CAR30, Memory-Enriched CART30."", ""2. Both HSP-CAR30 and Memory-Enriched CART30 are specific CAR-T cell therapies mentioned as being administered for treatment."", ""3. No secondary or comparator identifiers (e.g., 'with or without', 'vs', 'compared to') are present."", ""4. Excluded disease names and ensured only therapeutic agents are captured."", ""5. Applied formatting rules: preserved original casing and hyphenation."", ""6. Produced final JSON with both CAR-T variants as Primary Drugs.""]",True,1
5613,,Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results,,"[""Iptacopan""]",[],[],"[""1. Normalized title and identified candidate drug: Iptacopan."", ""2. 'Monotherapy' indicates Iptacopan is administered as the sole therapeutic agent."", ""3. No secondary or comparator drugs mentioned in the title."", ""4. Excluded broad therapy terms and ensured only the specific drug is captured."", ""5. Applied formatting rules and produced final JSON.""]",True,1
66,,"Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6",,"[""DISC-3405""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: DISC-3405, Recombinant Humanized Antibody, TMPRSS6."", ""2. DISC-3405 is specified as the investigational agent; 'Recombinant Humanized Antibody Targeting TMPRSS6' describes its mechanism, not a separate drug."", ""3. TMPRSS6 is a target, not a drug; excluded per exclusion rules."", ""4. No comparator or secondary drugs indicated in the title."", ""5. Applied formatting rules and outputted DISC-3405 as Primary.""]",True,1
3323,,"Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials",,"[""Cyclophosphamide"", ""Doxorubicin"", ""Vincristine"", ""Prednisolone"", ""Anti-CD20""]",[],[],"[""1. Normalized title and identified candidate drug/regimen phrases: Mini-CHOP, Anti-CD20."", ""2. Mini-CHOP is an attenuated regimen; per inclusion rules, expanded to its components: Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone."", ""3. 'Plus' indicates co-administration, so Anti-CD20 is also Primary."", ""4. No comparator or secondary identifiers present."", ""5. Excluded broad therapy term 'chemotherapy' per exclusion rules."", ""6. Applied formatting rules: listed individual drugs, maintained casing, used singular forms."", ""7. Produced final JSON output.""]",True,1
2640,,Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study,,"[""Rituximab"", ""Gemcitabine"", ""Oxaliplatin""]",[],[],"[""1. Normalized title and identified R-GemOx as a regimen used for treatment."", ""2. Checked for expanded drug names; R-GemOx is a regimen consisting of Rituximab, Gemcitabine, and Oxaliplatin."", ""3. Inclusion rules specify to expand regimen abbreviations when full drug names are not present."", ""4. No secondary or comparator drugs indicated in the title."", ""5. Applied formatting rules and outputted the expanded drug names as Primary.""]",True,1
1356,,Split-Dose R-CHOP for Older Patients with Treatment Naive DLBCL,,"[""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Vincristine"", ""Prednisolone""]",[],[],"[""1. Normalized title and identified 'R-CHOP' as a regimen for DLBCL treatment."", ""2. Applied inclusion rules: R-CHOP is an abbreviation; checked for expanded drug names in the title."", ""3. Expanded R-CHOP to its components: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone."", ""4. No secondary or comparator drugs indicated in the title."", ""5. Applied formatting rules: listed individual drug names, removed spaces around separators, used singular form."", ""6. Produced final JSON output.""]",True,1
1208,,Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy,,"[""CAR-T Cell""]",[],[],"[""1. Normalized title and identified candidate drug-related terms: CAR-T Therapy."", ""2. Applied cell therapy normalization: 'CAR-T Therapy' mapped to 'CAR-T Cell' per inclusion rules."", ""3. No other drug names or regimens detected; 'evolving management' is not a drug."", ""4. No comparator or secondary drugs identified."", ""5. Applied formatting rules and produced final JSON.""]",True,1
3863,,Preclinical Efficacy of Decoy-Resistant IL-18 in Hematological Malignancies,,"[""Decoy-Resistant IL-18""]",[],[],"[""1. Normalized title and identified candidate drug-like phrase: Decoy-Resistant IL-18"", ""2. 'Preclinical Efficacy of' indicates Decoy-Resistant IL-18 is the main agent being studied for therapeutic use"", ""3. No secondary or comparator identifiers present in the title"", ""4. Applied inclusion rules: Decoy-Resistant IL-18 is a laboratory-produced compound intended for treatment"", ""5. Formatted output per guidelines and verified no exclusions apply""]",True,1
2663,,Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma,,"[""18FDG""]",[],[],"[""1. Normalized title and identified candidate drug-like terms: 18FDG."", ""2. Detected '18FDG PET/CT' as a diagnostic agent used for imaging purposes."", ""3. Inclusion rules allow diagnostic agents if used for detection; 18FDG is included."", ""4. No therapeutic drugs or regimens mentioned; only 18FDG is present."", ""5. No secondary or comparator drugs identified."", ""6. Applied formatting rules and produced final JSON.""]",True,1
686,,"The Effectiveness of Levofloxacin in Prevention of Febrile Episodes in Non-Hodgkin Lymphoma Patients Receiving Rituximab, Cyclophosphamide, Vincristine, Doxorubicin and Prednisolone (R-CHOP)",,"[""Levofloxacin"", ""Rituximab"", ""Cyclophosphamide"", ""Vincristine"", ""Doxorubicin"", ""Prednisolone""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Levofloxacin, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone, R-CHOP."", ""2. Expanded R-CHOP to its component drugs and excluded the abbreviation per inclusion rules."", ""3. 'Levofloxacin in prevention' indicates Levofloxacin is administered for prevention, thus classified as Primary."", ""4. 'Patients receiving Rituximab, Cyclophosphamide, Vincristine, Doxorubicin and Prednisolone' indicates these drugs are also administered for treatment, so classified as Primary."", ""5. No identifiers for Secondary or Comparator drugs found."", ""6. Applied formatting rules: separated drugs with ';;', maintained title casing, and excluded R-CHOP abbreviation."", ""7. Produced final JSON output.""]",True,1
661,,"Combination of Mitoxantrone Hydrochloride Liposome with Gemcitabine, Cisplatin and Dexamethasone in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A Phase I Study",,"[""Mitoxantrone Hydrochloride Liposome"", ""Gemcitabine"", ""Cisplatin"", ""Dexamethasone""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Mitoxantrone Hydrochloride Liposome, Gemcitabine, Cisplatin, Dexamethasone."", ""2. The phrase 'Combination of ... with ... and ...' indicates all listed drugs are administered together as primary agents."", ""3. No secondary identifiers (e.g., 'with or without', '\u00b1') or comparator identifiers (e.g., 'vs', 'compared to') present."", ""4. Excluded non-drug terms and ensured all captured items are specific drug names per inclusion rules."", ""5. Applied formatting rules: preserved full drug names, used singular form, and separated drugs with ';;'."", ""6. Finalized output with all drugs classified as Primary and empty arrays for Secondary and Comparator.""]",True,1
2339,,"Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab (CMOP+-R) Shows High Efficacy As a First-Line Treatment for Non-Hodgkin's Lymphoma: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis",,"[""Cyclophosphamide"", ""Mitoxantrone Hydrochloride Liposome"", ""Vincristine"", ""Prednisone""]","[""Rituximab""]",[],"[""1. Normalized title and identified candidate drug phrases: Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, Prednisone, Rituximab."", ""2. Detected regimen structure: 'Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab'."", ""3. Applied inclusion rules: all four drugs in the regimen are included as Primary; 'with or without' indicates Rituximab is Secondary."", ""4. Excluded regimen abbreviation (CMOP+-R) since full drug names are present."", ""5. No comparator drugs identified as there is no explicit comparator arm in the title."", ""6. Applied formatting rules: separated drugs with ';;', maintained title casing, and singular forms."", ""7. Produced final JSON output.""]",True,1
335,,"Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia",,"[""Hyper-CVAD"", ""Inotuzumab Ozogamicin"", ""Blinatumomab""]","[""Inotuzumab Ozogamicin""]",[],"[""1. Normalized title and identified candidate drug/regimen phrases: Hyper-CVAD, Inotuzumab Ozogamicin, Blinatumomab."", ""2. 'with or without' indicates Inotuzumab Ozogamicin is a Secondary drug per classification guidelines."", ""3. 'and sequential' indicates Blinatumomab is administered as part of the regimen, thus Primary."", ""4. Hyper-CVAD is a regimen; no expanded drug names present, so included as Primary per inclusion rules."", ""5. No comparator phrases (vs, compared to, etc.) detected, so Comparator Drugs array is empty."", ""6. Applied formatting rules and verified output.""]",True,1
706,,"The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma",,"[""Rituximab"", ""Methotrexate"", ""Thiotepa"", ""Orelabrutinib"", ""Autologous Stem Cell""]",[],[],"[""1. Normalized title and identified candidate drug/regimen phrases: R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib), Autologous Stem Cell Transplantation."", ""2. Expanded R-MTO to its components: Rituximab, Methotrexate, Thiotepa, Orelabrutinib."", ""3. 'Followed by' indicates sequential administration, so Autologous Stem Cell Transplantation is also a primary therapy."", ""4. Applied stem cell therapy normalization: captured as 'Autologous Stem Cell'."", ""5. No comparator or secondary identifiers present."", ""6. Excluded broad therapy terms and ensured only drugs/cell therapies intended for treatment are included."", ""7. Formatted output per guidelines.""]",True,1
2076,,"Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group",,"[""Isatuximab"", ""Bortezomib"", ""Cyclophosphamide"", ""Dexamethasone"", ""Lenalidomide""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Isatuximab, Bortezomib, Cyclophosphamide, Dexamethasone, Lenalidomide."", ""2. 'in Combination with' and 'Followed By' indicate co-administration and sequential administration, both qualifying as Primary per guidelines."", ""3. No 'with or without', '\u00b1', 'and/or', or similar identifiers present, so no Secondary drugs."", ""4. No 'vs', 'versus', 'compared to', or similar comparator identifiers present, so no Comparator drugs."", ""5. Excluded broad therapy terms and ensured only drug names are captured."", ""6. Applied formatting rules: separated drugs with ;;, maintained title casing, and singular form."", ""7. Produced final JSON output.""]",True,1
4684,,"Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study",,"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone"", ""Daratumumab""]","[""Daratumumab""]",[],"[""1. Normalized title and identified candidate drug phrases: Bortezomib, Lenalidomide, Dexamethasone, Daratumumab."", ""2. Detected 'with or without Daratumumab' during induction/consolidation and maintenance, indicating Daratumumab as a secondary drug per classification guidelines."", ""3. 'Treated with Bortezomib, Lenalidomide and Dexamethasone' indicates these three as primary drugs; 'with or without Daratumumab' adds Daratumumab as both primary (when present) and secondary (optional) per rules."", ""4. No comparator drugs identified; no broad therapy terms or mechanisms present."", ""5. Applied formatting rules: separated drugs with ;;, maintained title casing, and excluded non-drug terms."", ""6. Produced final JSON output.""]",True,1
691,,"Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma",,"[""Zanubrutinib"", ""Rituximab"", ""Methotrexate""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Zanubrutinib, Rituximab, Methotrexate."", ""2. Detected 'in combination with' and 'followed by' as identifiers for co-primary administration."", ""3. 'Zanubrutinib in combination with Rituximab and Methotrexate' indicates all three are administered together as primary drugs."", ""4. 'Followed by Zanubrutinib maintenance' confirms Zanubrutinib is also used as maintenance, reinforcing its primary status."", ""5. No secondary or comparator drugs identified; excluded broad terms and ensured only therapeutic drugs are captured."", ""6. Applied formatting rules and produced final JSON.""]",True,1
337,,"Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update",,"[""Cyclophosphamide"", ""Vincristine"", ""Doxorubicin"", ""Dexamethasone"", ""Inotuzumab Ozogamicin""]","[""Blinatumomab""]",[],"[""1. Normalized title and identified candidate drug/regimen phrases: Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino), Blinatumomab (Blina)."", ""2. Mini-Hypercvd (mHCVD) is a regimen; expanded to component drugs: Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone (as per standard regimen composition)."", ""3. Inotuzumab Ozogamicin is listed as a main drug; included as Primary."", ""4. 'with/without' Blinatumomab indicates it is a Secondary drug per classification rules."", ""5. Excluded abbreviations (mHCVD, Ino, Blina) since expanded forms are present."", ""6. No comparator drugs identified."", ""7. Applied formatting rules and produced final JSON.""]",True,1
2505,,"A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome",,"[""Azacitidine"", ""Ipilimumab"", ""Nivolumab""]","[""Azacitidine""]",[],"[""1. Normalized title and identified candidate drug phrases: Azacitidine, Ipilimumab, Nivolumab."", ""2. Detected 'with' and 'or' as co-administration and alternative administration, indicating Primary drugs: Azacitidine, Ipilimumab, Nivolumab."", ""3. Found 'with or without Azacitidine' phrase, which per guidelines marks Azacitidine as Secondary in those arms."", ""4. No comparator identifiers ('vs', 'compared to', etc.) present, so Comparator Drugs array remains empty."", ""5. Applied formatting rules: singular drug names, proper casing, separator usage."", ""6. Finalized output JSON with step-by-step reasoning trace.""]",True,1
3338,,"Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma",,"[""Orelabrutinib"", ""Rituximab"", ""Thiotepa""]","[""High-Dose Methotrexate""]",[],"[""1. Normalized title and identified candidate drug phrases: Orelabrutinib, Rituximab, Thiotepa, High-Dose Methotrexate."", ""2. Detected 'in combination with or without' as the key identifier phrase."", ""3. Per guidelines, drugs before 'with or without' (Orelabrutinib, Rituximab, Thiotepa) are Primary; drugs after ('High-Dose Methotrexate') are Secondary."", ""4. Excluded 'ORT' as it is an abbreviation and all expanded drug names are present."", ""5. No comparator phrase detected."", ""6. Applied formatting rules and produced final JSON.""]",True,1
3705,,Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM),,"[""Personalized Neoantigen Peptide Vaccine""]","[""Lenalidomide""]",[],"[""1. Normalized title and identified candidate drug phrases: Personalized Neoantigen Peptide Vaccine, Lenalidomide."", ""2. 'with or without' is a key identifier for Secondary drug classification; Personalized Neoantigen Peptide Vaccine is administered with or without Lenalidomide."", ""3. Classified Personalized Neoantigen Peptide Vaccine as Primary and Lenalidomide as Secondary per guidelines."", ""4. No comparator phrases (vs, versus, compared to) detected; Comparator Drugs array left empty."", ""5. Applied formatting rules: maintained full drug names, singular form, and proper casing."", ""6. Produced final JSON output.""]",True,1
4980,,"Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial",,"[""Acalabrutinib"", ""Venetoclax""]","[""Obinutuzumab""]",[],"[""1. Normalized title and identified candidate drug phrases: Acalabrutinib, Venetoclax, Obinutuzumab, Chemoimmunotherapy."", ""2. 'Acalabrutinib plus Venetoclax' indicates co-primary administration; 'with or without Obinutuzumab' marks Obinutuzumab as Secondary."", ""3. 'Versus Chemoimmunotherapy' signals a comparator, but 'chemoimmunotherapy' is a broad therapy class and excluded per exclusion rules."", ""4. No other specific drugs or regimens are named as comparators."", ""5. Applied formatting rules: separated drugs with ;;, maintained title casing, and excluded broad therapy terms."", ""6. Produced final JSON with Acalabrutinib and Venetoclax as Primary, Obinutuzumab as Secondary, and no Comparator drugs.""]",True,1
2232,,"Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial",,"[""Daunorubicin"", ""Cytarabine""]","[""Cladribine""]",[],"[""1. Normalized title and identified candidate drug/regimen phrases: DA, cladribine."", ""2. DA is a common abbreviation for Daunorubicin and Cytarabine in AML regimens; no expanded form present, so included both drugs."", ""3. The phrase 'DA +/- cladribine' indicates DA (Daunorubicin, Cytarabine) as the main regimen, with cladribine as an optional addition."", ""4. Per guidelines, drugs after '+/-' (plus/minus) are classified as Secondary."", ""5. No comparator phrases (vs, compared to, etc.) detected."", ""6. Excluded general therapy terms and ensured only drugs intended for treatment are included."", ""7. Applied formatting rules: separated drugs with ';;', maintained title casing, and output as arrays.""]",True,1
1209,,Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone,,"[""Axicabtagene Ciloleucel""]","[""Dexamethasone""]",[],"[""1. Normalized title and identified candidate drug phrases: Axicabtagene Ciloleucel, Dexamethasone."", ""2. 'Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone' indicates Axicabtagene Ciloleucel is the main therapy and Dexamethasone is an optional/prophylactic addition."", ""3. The phrase 'with or without' signals Dexamethasone as a Secondary drug per classification guidelines."", ""4. No comparator drugs are present as there is no 'versus', 'compared to', or similar comparator language."", ""5. Applied formatting rules: proper casing, singular form, and correct separator usage."", ""6. Produced final JSON output.""]",True,1
514,,Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab,,"[""Crovalimab""]",[],[],"[""1. Normalized title and identified candidate drug names: Crovalimab, Eculizumab."", ""2. Detected 'switched from Eculizumab' indicates Eculizumab was prior therapy, not a comparator or co-administered drug."", ""3. Crovalimab is the only drug being evaluated for safety and efficacy in this trial."", ""4. Excluded Eculizumab per exclusion rule for prior therapies."", ""5. Classified Crovalimab as Primary."", ""6. No Secondary or Comparator drugs identified."", ""7. Applied formatting and output rules.""]",True,1
987,,A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma,,"[""CD19 CAR-T Cell""]","[""Rituximab""]",[],"[""1. Normalized title and identified candidate drug phrases: CD19 CAR T-Cells, Rituximab."", ""2. Detected 'with Escalating Doses of Lymphodepletion with or without Rituximab'\u2014'with or without' signals Secondary classification for Rituximab."", ""3. 'CD19 CAR T-Cells' is a specific cell therapy and included as Primary per inclusion rules."", ""4. Excluded 'lymphodepletion' as it is a procedure, not a drug."", ""5. No comparator drugs identified as there is no 'vs', 'compared to', or similar comparator phrase."", ""6. Applied formatting: normalized 'CD19 CAR T-Cells' to 'CD19 CAR-T Cell' per cell therapy rules."", ""7. Produced final JSON output.""]",True,1
1743,,"Preliminary Data of a Single-Arm, Phase II Study of Orelabrutinib with/without Rituximab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma after BTK Inhibitor Therapy",,"[""Orelabrutinib""]","[""Rituximab""]",[],"[""1. Normalized title and identified candidate drug phrases: Orelabrutinib, Rituximab, BTK Inhibitor."", ""2. Detected 'with/without' as the key identifier, indicating Orelabrutinib is always administered and Rituximab is optional (Secondary)."", ""3. 'after BTK Inhibitor Therapy' refers to prior treatment, so BTK Inhibitor is excluded per exclusion rules."", ""4. Classified Orelabrutinib as Primary and Rituximab as Secondary per guidelines."", ""5. Applied formatting rules and verified output structure.""]",True,1
4283,,"Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study",,"[""Motixafortide"", ""Natalizumab""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Motixafortide, Natalizumab."", ""2. Excluded mechanism terms (CXCR4 Inhibition, VLA-4 Inhibition) per exclusion rules."", ""3. Detected 'alone and in combination with' as an identifier for co-primary drugs."", ""4. No comparator or secondary identifiers present."", ""5. No regimens or cell therapies requiring normalization; 'Hematopoietic Stem Cells' are the target for mobilization, not administered as therapy."", ""6. Applied formatting rules and output final JSON.""]",True,1
3964,,Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data,,"[""Olutasidenib"", ""Azacitidine""]","[""Azacitidine""]",[],"[""1. Normalized title and identified candidate drug phrases: Olutasidenib, Azacitidine."", ""2. Detected the phrase 'Alone or in Combination with', which per guidelines marks the second drug (Azacitidine) as Secondary."", ""3. Both Olutasidenib and Azacitidine are administered for therapeutic use, so both are classified as Primary."", ""4. Azacitidine is also classified as Secondary due to the 'alone or in combination with' phrasing."", ""5. No comparator drugs or arms are mentioned."", ""6. Applied formatting rules and produced final JSON.""]",True,1
560,,"Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up",,"[""Gemtuzumab Ozogamicin"", ""Fludarabine"", ""Cytarabine"", ""G-CSF""]",[],"[""Idarubicin""]","[""1. Normalized title and identified candidate drug/regimen phrases: Gemtuzumab Ozogamicin, Fludarabine, Cytarabine, G-CSF (FLAG-GO), Idarubicin (FLAG-IDA)."", ""2. Expanded regimen abbreviations using full drug names as present; excluded regimen abbreviations since full names are available."", ""3. 'Added to' and 'and' indicate co-primary administration for Gemtuzumab Ozogamicin, Fludarabine, Cytarabine, and G-CSF."", ""4. 'Leads to...than' and comparison of FLAG-GO vs FLAG-IDA indicates Idarubicin is the comparator drug."", ""5. Excluded broad therapy terms and ensured only drugs intended for treatment are included."", ""6. Formatted output per guidelines, using singular forms and proper separators.""]",True,1
6012,,"SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)",,"[""Glofitamab"", ""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]",[],"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]","[""1. Normalized title and identified candidate drug/regimen phrases: Glofitamab, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Pola-R-CHP."", ""2. Recognized 'Pola-R-CHP' as an abbreviation for Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone; per rules, captured only the expanded drug names."", ""3. 'Glofitamab plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone' indicates all these drugs are administered together as the primary intervention."", ""4. 'Versus Pola-R-CHP' indicates the comparator arm, which is Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone."", ""5. No secondary drugs identified as there are no 'with or without' or similar secondary identifiers."", ""6. Applied formatting rules: used full drug names, separated by ;;, and maintained title casing."", ""7. Produced final JSON output.""]",True,1
569,,Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center,,"[""Fludarabine"", ""Cytarabine"", ""G-CSF"", ""Idarubicin"", ""Venetoclax""]",[],[],"[""1. Normalized title and identified candidate drug regimens: FLAG-Idarubicin and FLAG-Idarubicin Plus Venetoclax."", ""2. Expanded FLAG as Fludarabine, Cytarabine, and G-CSF per standard regimen definitions."", ""3. Idarubicin is explicitly named in both regimens."", ""4. Venetoclax is added in the 'Plus Venetoclax' arm."", ""5. 'Comparison of' indicates a comparative study, but both arms contain the same base drugs, with Venetoclax added in one arm."", ""6. No explicit 'versus' or 'compared to' phrase directly assigning Comparator status; both regimens are being evaluated for treatment."", ""7. All drugs in both regimens (Fludarabine, Cytarabine, G-CSF, Idarubicin, Venetoclax) are classified as Primary."", ""8. Applied formatting rules and output final JSON.""]",True,1
6089,,"Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma",,"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone"", ""Genotype-Guided Targeted Agents""]",[],"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]","[""1. Normalized title and identified candidate drug/regimen phrases: Genotype-Guided Targeted Agents, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, POLA-RCHP-X, Pola-Rchp."", ""2. Expanded POLA-RCHP-X and Pola-Rchp to their full drug components per inclusion rules; excluded regimen abbreviations since full names are present."", ""3. 'In combination with' indicates all listed drugs (Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Genotype-Guided Targeted Agents) are co-primary in the experimental arm."", ""4. 'Versus' indicates comparator arm; Pola-Rchp (Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone) is the comparator."", ""5. No secondary drugs identified as no 'with or without', '\u00b1', or similar secondary identifiers present."", ""6. Excluded broad therapy terms and ensured only drugs intended for treatment are captured."", ""7. Applied formatting rules: separated drugs with ';;', maintained title casing, and excluded regimen abbreviations."", ""8. Produced final JSON output.""]",True,1
1305,,Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma,,[],[],"[""EPOCH"", ""DCEP""]","[""1. Normalized title and identified candidate drug-like terms: EPOCH, DCEP."", ""2. Both EPOCH and DCEP are regimen abbreviations; no expanded drug names are present in the title."", ""3. The phrase 'Comparison of' indicates a head-to-head comparison, so both regimens are classified as Comparator Drugs."", ""4. No explicit primary or secondary drugs are mentioned; only regimens are compared."", ""5. Applied formatting rules: kept regimen abbreviations as no expanded forms are present."", ""6. Produced final JSON with Comparator Drugs as EPOCH and DCEP, Primary and Secondary arrays empty.""]",True,1
1216,,"Comparison of Tacrolimus/Methotrexate and Post-Transplant Cyclophosphamide Graft-Versus Host Disease Prophylaxis for Haploidentical and Matched Allogeneic Stem Cell Transplantation Demonstrates Improved Overall Survival and Reduced Mortality, Shorter Length of Stay, Less Peritransplant Toxicity with Post-Transplant Cyclophosphamide",,"[""Tacrolimus"", ""Methotrexate"", ""Post-Transplant Cyclophosphamide""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Tacrolimus/Methotrexate, Post-Transplant Cyclophosphamide."", ""2. 'Comparison of' indicates both regimens are being compared as primary interventions."", ""3. Tacrolimus/Methotrexate is a fixed combination, so separated into individual drugs per formatting rules."", ""4. Post-Transplant Cyclophosphamide is a specific drug regimen, included as a single drug per inclusion rules."", ""5. 'Graft-Versus Host Disease Prophylaxis' and transplantation terms are procedural, not drugs, and excluded."", ""6. No explicit comparator arm (e.g., 'vs', 'compared to') with a separate drug; both regimens are primary."", ""7. No secondary drugs identified per guidelines."", ""8. Applied formatting rules for separators and casing."", ""9. Produced final JSON output.""]",True,1
1217,,Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Espanol De Trasplante y Terapia Celular (GETH-TC),,"[""Treosulfan"", ""Fludarabine""]",[],"[""Thiotepa"", ""Busulfan"", ""Fludarabine""]","[""1. Normalized title and identified candidate drug regimens: Treosulfan/Fludarabine and Thiotepa/Busulfan/Fludarabine."", ""2. Split regimens into individual drug names: Treosulfan, Fludarabine, Thiotepa, Busulfan, Fludarabine."", ""3. Detected 'Versus' as the comparator identifier, indicating the first regimen (Treosulfan/Fludarabine) is Primary and the second (Thiotepa/Busulfan/Fludarabine) is Comparator."", ""4. Assigned Treosulfan and Fludarabine as Primary Drugs; Thiotepa, Busulfan, and Fludarabine as Comparator Drugs."", ""5. No secondary drug identifiers (e.g., 'with or without', 'and/or') present."", ""6. Applied formatting rules: separated drugs with ';;', maintained title casing, and excluded broad therapy terms."", ""7. Produced final JSON output.""]",True,1
3780,,High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI),,"[""Isatuximab"", ""Lenalidomide"", ""Dexamethasone"", ""Bortezomib""]",[],"[""Isard""]","[""1. Normalized title and identified candidate drug terms: Isatuximab (Isa), Lenalidomide, Dexamethasone (Rd), Bortezomib, Isard."", ""2. 'Plus' and 'and' indicate co-primary administration: Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib."", ""3. 'Versus' indicates a comparator arm: Isard."", ""4. Excluded regimen abbreviations (Isa, Rd) since full drug names are present."", ""5. No secondary drugs identified as no 'with or without', '\u00b1', or similar phrases."", ""6. Applied formatting rules: separated drugs with ;;, maintained title casing, and excluded any non-drug or broad therapy terms."", ""7. Produced final JSON with Primary and Comparator drugs appropriately classified.""]",True,1
2691,,"Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study",,"[""Isatuximab"", ""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]",[],"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]","[""1. Normalized title and identified candidate drug phrases: Isatuximab, Bortezomib, Lenalidomide, Dexamethasone, Isa-VRd, Vrd."", ""2. Expanded Isa-VRd and Vrd to their full drug components per inclusion rules."", ""3. Detected 'treated with ... and ...' indicating co-primary administration of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone."", ""4. 'Vs.' indicates comparator arm; Vrd alone refers to Bortezomib, Lenalidomide, and Dexamethasone as comparators."", ""5. Excluded regimen abbreviations (Isa-VRd, Vrd) since full drug names are present."", ""6. Applied formatting rules and produced final JSON.""]",True,1
4934,,"Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial",,"[""Belantamab Mafodotin"", ""Bortezomib"", ""Dexamethasone""]",[],"[""Daratumumab"", ""Bortezomib"", ""Dexamethasone""]","[""1. Normalized title and identified candidate drug phrases: Belantamab Mafodotin, Bortezomib, Dexamethasone, Daratumumab."", ""2. Detected 'Vs' as the comparator identifier, splitting the arms into two regimens."", ""3. First arm: Belantamab Mafodotin, Bortezomib, and Dexamethasone; classified all as Primary due to 'and' and co-administration."", ""4. Second arm: Daratumumab, Bortezomib, and Dexamethasone; classified all as Comparator as per 'Vs' structure."", ""5. No secondary drug identifiers (e.g., 'with or without', '\u00b1', 'and/or') present."", ""6. Applied formatting rules: proper casing, separator, and singular forms."", ""7. Produced final JSON output.""]",True,1
659,,Comparison of Efficacy and Safety of Gdpt and CHOP in First-Line Treatment of Peripheral T-Cell Lymphoma,,[],[],"[""GDPT"", ""CHOP""]","[""1. Normalized title and identified candidate drug regimens: GDPT and CHOP."", ""2. Both GDPT and CHOP are regimen abbreviations; no expanded drug names are present in the title."", ""3. 'Comparison of' and 'in' indicate a head-to-head study, so both regimens are comparators."", ""4. No explicit primary or secondary drugs are mentioned; only regimens are compared."", ""5. Applied formatting rules: kept regimen abbreviations as no expanded forms are present."", ""6. Produced final JSON with GDPT and CHOP as Comparator Drugs.""]",True,1
2074,,"Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial",,"[""Belantamab Mafodotin"", ""Bortezomib"", ""Dexamethasone""]",[],"[""Daratumumab"", ""Bortezomib"", ""Dexamethasone""]","[""1. Normalized title and identified candidate drug phrases: Belantamab Mafodotin, Bortezomib, Dexamethasone, Daratumumab."", ""2. Detected 'plus' and 'and' indicating co-administration for Belantamab Mafodotin, Bortezomib, and Dexamethasone (Primary arm)."", ""3. Detected 'vs' indicating comparator arm: Daratumumab, Bortezomib, and Dexamethasone."", ""4. Applied inclusion rules to capture all drug names as stated; excluded any broad therapy terms (none present)."", ""5. Assigned Belantamab Mafodotin, Bortezomib, and Dexamethasone as Primary Drugs; Daratumumab, Bortezomib, and Dexamethasone as Comparator Drugs."", ""6. No secondary drug identifiers found."", ""7. Applied formatting rules and validated output.""]",True,1
4668,,PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601,,"[""ABVD"", ""Bv+AVD"", ""Nivolumab""]",[],[],"[""1. Normalized title and identified candidate drug/regimen phrases: ABVD, Bv+AVD, Nivolumab."", ""2. Detected 'with' and 'followed by' as indicators of co-primary administration; 'Vs.' suggests a comparison but both arms are specified, so both are primary."", ""3. ABVD and Bv+AVD are regimens; no expanded forms present, so kept regimen abbreviations."", ""4. 'Followed by Nivolumab' indicates Nivolumab is part of the primary treatment sequence."", ""5. No secondary or comparator drugs identified as all drugs are part of the main treatment arms."", ""6. Applied formatting rules and output final JSON.""]",True,1
4822,,Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma,,"[""Carfilzomib"", ""Lenalidomide"", ""Dexamethasone""]",[],"[""Lenalidomide"", ""Dexamethasone""]","[""1. Normalized title and identified candidate drug regimens: Carfilzomib-Lenalidomide-Dexamethasone and Lenalidomide-Dexamethasone."", ""2. Parsed the 'Vs' (versus) identifier, indicating a comparison between two regimens."", ""3. Broke down regimens into individual drugs: Carfilzomib, Lenalidomide, Dexamethasone."", ""4. Assigned Carfilzomib, Lenalidomide, Dexamethasone as Primary (experimental arm); Lenalidomide, Dexamethasone as Comparator (control arm)."", ""5. Applied formatting rules: separated drugs with ';;', maintained title casing, and excluded any non-drug terms."", ""6. Produced final JSON output.""]",True,1
1041,,"Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study",,"[""Daratumumab"", ""Pomalidomide"", ""Dexamethasone"", ""Carfilzomib""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib."", ""2. Detected two regimens: Daratumumab, Pomalidomide, Dexamethasone and Daratumumab, Carfilzomib, Dexamethasone."", ""3. 'Compared to' indicates a comparison between two regimens, but both regimens are composed of specific drugs and not a single comparator arm."", ""4. All drugs are administered for therapeutic use in the study arms, so classified all as Primary."", ""5. No secondary or explicit comparator drugs per classification rules."", ""6. Applied formatting rules and produced final JSON.""]",True,1
6067,,A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209,,"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone"", ""Daratumumab""]","[""Lenalidomide"", ""Daratumumab""]",[],"[""1. Normalized title and identified candidate drug phrases: Bortezomib, Lenalidomide, Dexamethasone, Daratumumab."", ""2. Detected two regimens: VRd-Lite (Bortezomib, Lenalidomide, Dexamethasone) and DRd (Daratumumab, Lenalidomide, Dexamethasone)."", ""3. 'Comparing' indicates a head-to-head trial, but both arms are experimental regimens, so all drugs in both arms are classified as Primary."", ""4. 'Len maintenance' and 'Len+/- Dara Maintenance' indicate maintenance therapy with Lenalidomide with or without Daratumumab; '+/-' triggers Secondary classification for Lenalidomide and Daratumumab in maintenance."", ""5. Excluded regimen abbreviations (VRd-Lite, DRd) since expanded drug names are present."", ""6. No explicit comparator arm (e.g., standard of care or placebo), so Comparator Drugs array is empty."", ""7. Applied formatting rules and validated output.""]",True,1
1758,,Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia,,"[""Eltrombopag""]",[],"[""Haploidentical Hematopoietic Stem Cell""]","[""1. Normalized title and identified candidate drug-related phrases: Haploidentical Hematopoietic Stem Cell Transplantation, Eltrombopag, Standard Immunosuppression."", ""2. 'Comparisons between' indicates a comparative study; the two arms are Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag plus Standard Immunosuppression."", ""3. Per stem cell therapy normalization, 'Haploidentical Hematopoietic Stem Cell Transplantation' is captured as 'Haploidentical Hematopoietic Stem Cell'."", ""4. 'Eltrombopag adding to standard immunosuppression' indicates Eltrombopag is the main drug being evaluated; 'standard immunosuppression' is a broad therapy class and excluded per exclusion rules."", ""5. Classified Eltrombopag as Primary and Haploidentical Hematopoietic Stem Cell as Comparator."", ""6. No secondary drugs identified as there are no 'with or without' or similar secondary indicators."", ""7. Applied formatting and output final JSON.""]",True,1
6094,,"Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody",,"[""Talquetamab"", ""Pomalidomide"", ""Teclistamab""]",[],"[""Elotuzumab"", ""Pomalidomide"", ""Dexamethasone"", ""Bortezomib""]","[""1. Normalized title and identified all drug-like terms and regimens."", ""2. Detected Talquetamab + Pomalidomide and Talquetamab + Teclistamab as primary arms due to 'Phase 3 Study of' and 'or' indicating co-primary regimens."", ""3. Identified 'Vs' as the comparator indicator, separating comparator arms: Elotuzumab + Pomalidomide + Dexamethasone (EPd) and Pomalidomide + Bortezomib + Dexamethasone (PVd)."", ""4. Expanded EPd and PVd to their full drug components as per inclusion rules."", ""5. Excluded 'Lenalidomide' and 'Anti-CD38 Monoclonal Antibody' as they are only mentioned as prior therapies, not as study drugs."", ""6. No secondary drugs identified as no 'with or without' or similar secondary identifiers present."", ""7. Applied formatting rules: separated drugs with ';;', maintained title casing, and excluded broad therapy terms."", ""8. Produced final JSON output.""]",True,1
4065,,"Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China",,"[""Ixazomib"", ""Lenalidomide"", ""Dexamethasone""]",[],"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]","[""1. Normalized title and identified candidate drug phrases: Ixazomib, Lenalidomide, Dexamethasone, Bortezomib."", ""2. Detected regimens IRd (Ixazomib, Lenalidomide, Dexamethasone) and VRd (Bortezomib, Lenalidomide, Dexamethasone); expanded abbreviations per inclusion rules."", ""3. 'Comparison of' and 'and' indicate two arms; first arm (IRd) is Primary, second arm (VRd) is Comparator."", ""4. Both regimens contain Lenalidomide and Dexamethasone, so these are included in both Primary and Comparator categories."", ""5. Applied formatting rules: separated drugs with ;;, maintained title casing, and excluded regimen abbreviations since full drug names are present."", ""6. Produced final JSON output.""]",True,1
3754,,"Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study",,"[""Selinexor"", ""Bortizomib"", ""Dexamethasone""]",[],"[""Bortizomib"", ""Dexamethasone""]","[""1. Normalized title and identified candidate drug phrases: Selinexor, Bortizomib, Dexamethasone, SVd, Vd."", ""2. Expanded SVd to Selinexor, Bortizomib, Dexamethasone and Vd to Bortizomib, Dexamethasone; excluded abbreviations since full names are present."", ""3. Detected 'versus' as a comparator identifier, indicating two arms: SVd (weekly) vs Vd (twice weekly)."", ""4. Classified Selinexor, Bortizomib, Dexamethasone (from SVd) as Primary Drugs (experimental arm)."", ""5. Classified Bortizomib, Dexamethasone (from Vd) as Comparator Drugs (control arm)."", ""6. No secondary drug identifiers found."", ""7. Applied formatting rules and validated output.""]",True,1
4151,,Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study,,"[""Glofitamab"", ""Gemcitabine"", ""Oxaliplatin""]",[],"[""Rituximab"", ""Gemcitabine"", ""Oxaliplatin""]","[""1. Normalized title and identified candidate drug phrases: Glofitamab, Gemcitabine, Oxaliplatin, Rituximab."", ""2. Detected regimens: Glofit-GemOx (Glofitamab plus Gemcitabine and Oxaliplatin) and R-GemOx (Rituximab plus Gemcitabine and Oxaliplatin)."", ""3. 'Plus' and 'and' indicate co-primary administration for Glofitamab, Gemcitabine, and Oxaliplatin."", ""4. 'Versus' signals comparator arm: Rituximab plus Gemcitabine and Oxaliplatin."", ""5. Expanded regimen abbreviations to full drug names per inclusion rules."", ""6. Excluded broad therapy terms and ensured only drugs intended for treatment are captured."", ""7. Applied formatting rules and produced final JSON.""]",True,1
3971,,Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant,,"[""Glofitamab"", ""Gemcitabine"", ""Oxaliplatin""]",[],"[""Rituximab"", ""Gemcitabine"", ""Oxaliplatin""]","[""1. Normalized title and identified candidate drug phrases: Glofitamab, Gemcitabine, Oxaliplatin, Rituximab."", ""2. Detected 'with' and 'and' indicating co-administration for both arms; 'versus' signals comparator arm."", ""3. Classified Glofitamab, Gemcitabine, Oxaliplatin as Primary (first regimen); Rituximab, Gemcitabine, Oxaliplatin as Comparator (second regimen)."", ""4. Excluded 'Autologous Stem Cell Transplant' per cell therapy rules since it is not administered in this context (patients not candidates)."", ""5. Applied formatting rules: separated drugs with ;;, maintained title casing, and excluded broad therapy terms."", ""6. Produced final JSON output.""]",True,1
5996,,"Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy",,"[""Venetoclax"", ""Azacitidine"", ""Cusatuzumab""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Venetoclax, Azacitidine, Cusatuzumab."", ""2. Detected 'plus' and 'versus' as key identifiers; 'Venetoclax and Azacitidine plus Cusatuzumab' vs 'Venetoclax and Azacitidine alone'."", ""3. 'Plus' indicates co-primary administration; 'alone' arm uses Venetoclax and Azacitidine as primary drugs."", ""4. 'Versus' sets up a comparator, but both arms use Venetoclax and Azacitidine, with Cusatuzumab added in one arm; no separate comparator drug is present."", ""5. Excluded general therapy terms and ensured only drugs intended for treatment are captured."", ""6. Applied formatting rules and outputted final JSON.""]",True,1
4796,,"Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial",,"[""Decitabine"", ""All-Trans Retinoic Acid""]",[],"[""Decitabine""]","[""1. Normalized title and identified candidate drug phrases: Decitabine, All-Trans Retinoic Acid."", ""2. 'Plus' indicates co-administration, so Decitabine and All-Trans Retinoic Acid are Primary drugs."", ""3. 'Versus' indicates a comparator arm; Decitabine Monotherapy is the comparator, so Decitabine is listed as Comparator."", ""4. Excluded broad therapy terms and ensured only drug names are captured per inclusion/exclusion rules."", ""5. Applied formatting rules: proper casing, separator, and singular form."", ""6. Produced final JSON output.""]",True,1
4960,,A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL),,"[""Mosunetuzumab"", ""Polatuzumab Vedotin""]",[],"[""Rituximab"", ""Polatuzumab Vedotin""]","[""1. Normalized title and identified candidate drug phrases: Mosunetuzumab SC, Polatuzumab Vedotin, Rituximab, Polatuzumab Vedotin."", ""2. 'Mosunetuzumab SC plus Polatuzumab Vedotin' indicates co-primary administration; 'versus' signals comparator arm."", ""3. In comparator arm, 'Rituximab plus Polatuzumab Vedotin' are both comparators."", ""4. Excluded 'SC' (subcutaneous) per exclusion rules (route of administration)."", ""5. Applied formatting rules: removed spaces, used singular drug names, and proper casing."", ""6. Final classification: Mosunetuzumab and Polatuzumab Vedotin as Primary; Rituximab and Polatuzumab Vedotin as Comparator.""]",True,1
549,,"Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML",,"[""Venetoclax"", ""Azacitidine"", ""Chidamide""]",[],[],"[""1. Normalized title and identified candidate drug regimens: VAC (Venetoclax, Azacitidine, Chidamide) and VA."", ""2. Expanded VAC to its full drug components: Venetoclax, Azacitidine, Chidamide."", ""3. VA regimen is not expanded in the title; per inclusion rules, do not capture VA as a regimen or as individual drugs unless expanded."", ""4. 'Comparing' indicates a comparison, but both regimens are experimental arms, not a standard comparator; no explicit comparator drug is named."", ""5. Excluded general terms and ensured only drugs intended for treatment are captured."", ""6. Applied formatting rules and output the final JSON.""]",True,1
2954,,"Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)",,"[""Recombinant Human Thrombopoietin""]",[],"[""Eltrombopag""]","[""1. Normalized title and identified candidate drug phrases: Recombinant Human Thrombopoietin (rhTPO), Eltrombopag."", ""2. 'Regimen Versus' indicates a comparison; the first regimen is the primary drug, the second is the comparator."", ""3. Expanded abbreviation rhTPO to full name per inclusion rules."", ""4. Excluded 'pre-treated' context drugs as per exclusion rules; only drugs intended for current treatment are captured."", ""5. Classified Recombinant Human Thrombopoietin as Primary and Eltrombopag as Comparator."", ""6. Applied formatting rules and produced final JSON.""]",True,1
2422,,Lymphodepletion with Fludarabine/Cyclophosphamide Shows Higher Complete Response Rates Compared to Bendamustine Prior to CAR-T Therapy,,"[""Fludarabine"", ""Cyclophosphamide"", ""Bendamustine""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Fludarabine, Cyclophosphamide, Bendamustine, CAR-T Therapy."", ""2. 'Fludarabine/Cyclophosphamide' indicates a regimen used for lymphodepletion; both drugs are captured individually per inclusion rules."", ""3. 'Compared to Bendamustine' suggests a comparison, but all drugs are used as pre-treatment regimens prior to CAR-T Therapy, not as comparator arms in the context of the main therapy."", ""4. 'Prior to CAR-T Therapy' indicates these drugs are administered before CAR-T, but CAR-T Therapy itself is not the focus of the comparison and is excluded as per cell therapy rules (not administered in this context)."", ""5. Excluded 'CAR-T Therapy' since the title focuses on lymphodepletion regimens, not CAR-T as a treatment arm."", ""6. Classified Fludarabine, Cyclophosphamide, and Bendamustine as Primary Drugs since they are the main agents being evaluated for their effect on response rates."", ""7. No secondary or comparator drugs identified per classification guidelines."", ""8. Applied formatting rules and produced final JSON.""]",True,1
2125,,Comparison of Rabbit ATLG and ATG in Allogeneic Hematopoietic Stem Cell Transplantation for Children with Acquired Severe Aplastic Anemia,,"[""Rabbit ATLG"", ""ATG""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: Rabbit ATLG, ATG, Allogeneic Hematopoietic Stem Cell Transplantation."", ""2. Applied inclusion rules: Rabbit ATLG and ATG are drug names; Allogeneic Hematopoietic Stem Cell Transplantation is a procedure, not a drug, so excluded."", ""3. Detected 'Comparison of' as a comparator identifier, but both drugs are being compared directly, so both are classified as Primary per guidelines."", ""4. No secondary drugs identified; no explicit comparator arm beyond the two drugs."", ""5. Applied formatting rules and verified output.""]",True,1
4404,,A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial,,"[""Low-Dose Cytarabine"", ""Venetoclax""]","[""Midostaurin""]",[],"[""1. Normalized title and identified candidate drug phrases: Low-Dose Cytarabine, Venetoclax, Midostaurin."", ""2. Detected 'comparing' as a trial design keyword, but no explicit comparator drug arm is specified; focus is on regimens."", ""3. The '+/-' (plus/minus) symbol indicates that Midostaurin is administered optionally, classifying it as Secondary per guidelines."", ""4. 'Low-Dose Cytarabine and Venetoclax' are co-administered as the main regimen, classified as Primary."", ""5. No comparator drug is specified; excluded general terms and ensured only therapeutic drugs are captured."", ""6. Applied formatting rules for drug names and output structure.""]",True,1
3641,,Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial,,"[""Bortezomib"", ""Melphalan"", ""Prednisone"", ""Daratumumab"", ""Lenalidomide"", ""Dexamethasone""]","[""Daratumumab""]",[],"[""1. Normalized title and identified candidate drug regimens: VMP (Bortezomib, Melphalan, Prednisone), DVMP (VMP + Daratumumab), Rd (Lenalidomide, Dexamethasone), DRd (Rd + Daratumumab)."", ""2. Expanded all regimen abbreviations to full drug names per inclusion rules."", ""3. '+/- daratumumab' indicates Daratumumab is a secondary drug in both arms, but also present in primary combinations."", ""4. 'vs.' indicates comparison between VMP +/- Daratumumab and Rd +/- Daratumumab, but no distinct comparator drug outside the regimens."", ""5. Classified Bortezomib, Melphalan, Prednisone, Daratumumab, Lenalidomide, Dexamethasone as Primary (all are administered for treatment); Daratumumab also as Secondary due to '+/-' (with or without) phrasing."", ""6. No separate comparator drug outside the regimens; left Comparator Drugs empty."", ""7. Applied formatting rules and produced final JSON.""]",True,1
185,,Beyond Classical Hodgkin Lymphoma: Long-Term Risks and Secondary Cancers-Insights from the Texas Cancer Registry,,[],[],[],"[""1. Normalized title and searched for drug-like phrases or regimens."", ""2. Detected no drug names, regimens, cell therapies, or therapeutic agents in the title."", ""3. Title focuses on risks and secondary cancers, not on treatment or drug administration."", ""4. No inclusion or comparator identifiers present."", ""5. Per inclusion and exclusion rules, no drugs to extract; returned empty arrays.""]",True,1
289,,Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease,,[],[],[],"[""1. Normalized title and scanned for drug-like terms or regimens."", ""2. Detected no specific drug names, regimens, or cell therapies; only general terms like 'Artificial Intelligence' and 'Personalized Medicine' present."", ""3. 'Sickle Cell Disease' is a disease, not a drug or therapy."", ""4. No inclusion rule matches; no drugs intended for treatment are mentioned."", ""5. Output empty arrays for all drug categories as per instructions.""]",True,1
319,,CSF3RT618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL),,[],[],[],"[""1. Normalized title and tokenized for drug-like phrases."", ""2. Identified CSF3RT618I, Calnexin, and CSF3R proteins as candidate terms."", ""3. CSF3RT618I and CSF3R proteins are genetic mutations/proteins, not administered drugs; Calnexin is a chaperone protein, not a therapeutic agent."", ""4. No drug, regimen, cell therapy, or vaccine intended for treatment is mentioned."", ""5. Excluded all terms per exclusion rules (proteins, genetic mutations, mechanisms, not drugs)."", ""6. Returned empty arrays for all drug categories.""]",True,1
340,,Results of the ALL-IC REL 2016 Registry Trial: 1st Relapses of Childhood ALL Treated in High-Middle Income Countries,,[],[],[],"[""1. Normalized title and searched for drug names, regimens, or cell therapies."", ""2. Detected no explicit drug names, regimens, or cell therapies in the title."", ""3. 'ALL-IC REL 2016 Registry Trial' is a study name, not a drug or regimen."", ""4. '1st Relapses of Childhood ALL Treated' describes the patient population, not a therapy."", ""5. No drugs intended for treatment are mentioned; all arrays left empty per guidelines.""]",True,1
408,,Real World Data on the Utility of P-Selectin Expression Assay; Correlation of Test Results and Disease Expression,,[],[],[],"[""1. Normalized title and identified candidate phrases: P-Selectin Expression Assay."", ""2. Evaluated context: 'assay' refers to a diagnostic test, not a therapeutic drug or regimen."", ""3. No drugs or regimens intended for treatment, cure, mitigation, or prevention are mentioned."", ""4. Excluded diagnostic agents per exclusion rules unless used therapeutically, which is not the case here."", ""5. No drugs identified; output empty arrays for all categories.""]",True,1
450,,"TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial",,"[""Rituximab"", ""Bendamustine"", ""Cytarabine""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: TP53, CD36, CDKN2A, V-Rbac."", ""2. TP53, CD36, and CDKN2A are gene/mutation names, not drugs; excluded per exclusion rules."", ""3. V-Rbac is an abbreviated regimen; expanded to Rituximab, Bendamustine, Cytarabine per standard oncology regimen knowledge."", ""4. No comparator or secondary drug identifiers present in the title."", ""5. Applied formatting rules: listed individual drugs, removed spaces, used singular forms."", ""6. Finalized output JSON with Primary Drugs only.""]",True,1
503,,Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study,,[],[],[],"[""1. Normalized title and searched for drug-like terms or regimens."", ""2. No specific drug names, regimens, or cell therapies are mentioned in the title."", ""3. 'Second Line Therapy' is a general therapy term and excluded per exclusion rules."", ""4. No drugs identified for Primary, Secondary, or Comparator categories."", ""5. Output empty arrays for all drug categories as per instructions.""]",True,1
620,,Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry,,"[""Bruton Tyrosine Kinase Inhibitor""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: Bruton Tyrosine Kinase Inhibitor, Chemotherapy."", ""2. 'Sequential Bruton Tyrosine Kinase Inhibitor Therapy' indicates the main therapeutic agent studied; 'Chemotherapy' is mentioned as prior therapy, not as a treatment under investigation."", ""3. Excluded 'Chemotherapy' per exclusion rules (broad therapy term and prior therapy context)."", ""4. Classified 'Bruton Tyrosine Kinase Inhibitor' as Primary based on its role as the main treatment."", ""5. No secondary or comparator drugs identified."", ""6. Applied formatting rules and produced final JSON.""]",True,1
641,,"Real World Treatment Outcomes in the First Line Management of Waldenstrom Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical",,[],[],[],"[""1. Normalized title and searched for drug-like phrases."", ""2. No specific drug names, regimens, cell therapies, or therapeutic agents identified in the title."", ""3. 'First Line Management' and 'Treatment Outcomes' are general therapy terms and excluded per exclusion rules."", ""4. No drugs intended for treatment are mentioned; all arrays left empty."", ""5. Final output formatted as per instructions.""]",True,1
801,,Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations,,[],[],[],"[""1. Normalized title and identified candidate terms: Adolescents and Young Adults, Myeloproliferative Neoplasms, High-Molecular Risk Mutations."", ""2. No drug names, regimens, cell therapies, or vaccines are mentioned in the title."", ""3. 'High-Molecular Risk Mutations' refers to genetic risk factors, not a drug or therapy."", ""4. No therapeutic agents are described as being administered for treatment, cure, mitigation, or prevention."", ""5. Per inclusion and exclusion rules, no drugs are extracted; all output arrays are empty.""]",True,1
919,,Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial,,"[""Gene Therapy""]",[],[],"[""1. Normalized title and identified candidate therapeutic terms: Gene Therapy."", ""2. Evaluated inclusion rules: Gene Therapy is a laboratory-produced compound administered for treatment."", ""3. No other drug names, regimens, cell therapies, or comparators detected."", ""4. 'Gene Therapy' is the main intervention studied, classified as Primary."", ""5. Applied formatting rules and produced final JSON.""]",True,1
968,,Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party,,"[""Hematopoietic Cell""]",[],[],"[""1. Normalized title and identified candidate therapeutic terms."", ""2. Detected 'Haemopoietic Cell Transplantation' as a cell therapy for transfusion dependent thalassaemia."", ""3. Applied stem cell therapy normalization: removed 'transplantation' and captured 'Hematopoietic Cell' per inclusion rules."", ""4. No other drug names, regimens, or comparators present."", ""5. Excluded broad therapy terms and mechanisms per exclusion rules."", ""6. Formatted output per guidelines and produced final JSON.""]",True,1
1023,,Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry,,[],[],[],"[""1. Normalized title and searched for drug-like phrases."", ""2. Detected only references to chromosomal abnormalities and disease registry, no drug names or regimens present."", ""3. No therapeutic agents, cell therapies, or regimens identified for treatment."", ""4. Excluded all non-drug terms per exclusion rules."", ""5. Returned empty arrays for all drug categories.""]",True,1
1043,,Real World Efficacies of First Line Treatments in Non-Transplant-Eligible Newly Diagnosed (ND-NTE) Multiple Myeloma (MM) Patients: A Challenge to Maia ? an Analysis from the Austrian Myeloma Registry (AMR),,[],[],[],"[""1. Normalized title and searched for drug names, regimens, or cell therapies."", ""2. Detected only general terms: 'First Line Treatments', 'Non-Transplant-Eligible', and reference to the 'Maia' study, but no specific drug or regimen names."", ""3. 'Maia' refers to a clinical trial, not a drug or regimen itself."", ""4. No explicit drug, regimen, or cell therapy intended for treatment is mentioned."", ""5. Per exclusion rules, general therapy terms and study references are not captured."", ""6. Output empty arrays for all categories.""]",True,1
1061,,Health Resource Utilization Among Patients with Warm Autoimmune Hemolytic Anemia in Sweden: A Retrospective Registry-Based Study,,[],[],[],"[""1. Normalized title and searched for drug-like phrases."", ""2. No drug names, regimens, cell therapies, or therapeutic agents detected in the title."", ""3. The study focuses on health resource utilization and disease context, not on drug administration."", ""4. No inclusion or exclusion rules triggered; no drugs to extract."", ""5. Returned empty arrays for all drug categories.""]",True,1
1098,,Complementary and Alternative Medicine (CAM) Use Reported Among Individuals with Immune Thrombocytopenia (ITP): Data from the ITP Natural History Study Registry,,[],[],[],"[""1. Normalized title and identified candidate terms: Complementary and Alternative Medicine (CAM)"", ""2. 'Complementary and Alternative Medicine' is a broad therapy class, not a specific drug or regimen"", ""3. No specific drug names, regimens, or cell therapies are mentioned in the title"", ""4. Excluded broad therapy terms per exclusion rules"", ""5. No drugs identified for any category; returned empty arrays""]",True,1
1123,,Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas,,[],[],[],"[""1. Normalized title and tokenized for drug-like phrases."", ""2. Detected no drug names, regimens, cell therapies, or diagnostic agents; only registry and biorepository terms present."", ""3. 'Clonal Hematopoiesis' and 'Inflammation' are biological processes, not drugs or therapies."", ""4. No therapeutic agents or drug-related identifiers found."", ""5. Output empty arrays for all drug categories per inclusion/exclusion rules.""]",True,1
1171,,Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial,,[],[],[],"[""1. Normalized title and identified key phrases: Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), Dose Review, Phase I Clinical Trial."", ""2. No drug names, regimens, cell therapies, or vaccines are mentioned in the title."", ""3. 'PRO-CTCAE' is a reporting tool, not a drug or therapeutic agent."", ""4. 'Dose Review' and 'Phase I Clinical Trial' refer to study design, not specific drugs."", ""5. No drugs intended for treatment are present; all arrays left empty per guidelines.""]",True,1
1290,,Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis,,[],[],[],"[""1. Normalized title and searched for drug names or regimens."", ""2. Detected only general terms: 'Treatment', 'Treatment Patterns', and 'Outcomes', with no specific drug or regimen mentioned."", ""3. Excluded broad therapy terms per exclusion rules."", ""4. No drugs identified for any category; returned empty arrays.""]",True,1
